FindTrial
Sign In

Efficacy and safety of different strategies in patients with progression after first-line systemic therapy for primary liver cancer: a prospective, observational cohort study

Efficacy and safety of different strategies in patients with progression after first-line systemic therapy for primary liver cancer: a prospective, observational cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500108250
Enrollment
Unknown
Registered
2025-08-27
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary liver cancer

Interventions

Observation group:None

Sponsors

The 5th Medical Center of PLA General Hospital, Beijing, China.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. The patient is at least 18 years old; 2. Pathologically diagnosed as hepatocellular carcinoma by liver biopsy and received standard first-line anti-tumor system treatment; 3. Tumor progression occurs under the premise that first-line treatment effectively controls tumors (no tumor progression occurs within 3 months of medication); 4. Child-Pugh is graded as A-B(8); 5. ECOG PS score 0-2 points; 6. Have at least 1 measurable target lesion according to the RECIST1.1 criteria.

Exclusion criteria

Exclusion criteria: 1. Severe comorbidities of any other vital organs; 2. The patient has other malignant tumors in the past or present; 3. Those with incomplete medical records.

Design outcomes

Primary

MeasureTime frame
Overall survival;Progressive free survival;—

Countries

China

Contacts

Public ContactCheng Jiamin

The 5th Medical Center of PLA General Hospital, Beijing, China.

yhlwherever@qq.com+86 10 6693 3380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026